MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...

REDWOOD CITY, Calif., March 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna ...

Exact Sciences' approach in multi-cancer early detection (MCED) confirmed in first-ever, long-term, follow-up data from an MCED trial1-2 Surveillance, Epidemiology, and End Results (SEER) program ...

New ASCO Recommendations Increase Proportion of Women Who Can Be Spared Chemotherapy Based on Landmark TAILORx and NSABP B-20 Randomized Clinical Trials Additional Secondary Analysis of TAILORx Trial ...

Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...

Pertuzumab/Docetaxel/Carboplatin/Trastuzumab Regimen in Human Epidermal Growth Factor Receptor 2–Positive Early, Locally Advanced, and Oligometastatic Breast Cancer ...

Gene expression testing, such as Oncotype DX, aids in chemotherapy decisions for hormone receptor-positive breast cancer, though challenges exist for premenopausal patients with scores under 25.

In what's believed to be one of the largest population-based studies of Oncotype DX ever conducted, researchers at The University of Texas MD Anderson Cancer Center have found that the commercial ...

The NCCN Clinical Practice Guidelines in Oncology cites the test as a recommendation to determine treatment for patients with ER-positive, HER2-negative tumors without axillary lymph node metastases.